Avalo Therapeutics is a clinical stage biotechnology company focused on the treatment of immune dysregulation. Avalo’s lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases.
For more information about Avalo, please visit www.avalotx.com.
Our highly targeted therapeutics have strong scientific and clinical rationale that enable accelerated clinical development and increased probability of success.
We are rapidly advancing a rich pipeline with broad clinical utility across Immunology, Immuno-oncology, and Rare Genetic Diseases.
Our focus is the development of innovative therapies in areas of high unmet need within the fields of Rare Pediatric and Orphan Diseases.